CTLA4 and metastatic melanoma: This led to Food and Drug Administration (FDA) approval of ipilimumab (Yervoy), an anti-cytotoxic T lymphocyte associated protein-4 (anti-CTLA4) antibody, in 2011 for the treatment of newly diagnosed or previously treated unresectable/metastatic melanoma.